Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 364 participants.

Also called NCT02494284

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 364 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02494284
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02494284. Randomized; no masking; primary purpose treatment. Start 2015-12-22 (actual); primary completion 2017-02-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation
Acronym
STAMP-DES
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Aspirin plus clopidogrel
Lead sponsor
CHEOL WHAN LEE, M.D., Ph.D (class: other)
Collaborator
CardioVascular Research Foundation, Korea (class: other)
Collaborator
Medtronic (class: industry)
Collaborator
Chong Kun Dang Pharmaceutical Corp. (class: industry)

Record details

Record id
cardio:ct-nct02494284
Content hash
9a6eab178b502791673351db9ae3c8a7c9558c7531686a8adcfedc341dabeefe